RBD 7022
Alternative Names: RBD-7022Latest Information Update: 24 Aug 2023
At a glance
- Originator Suzhou Ribo Life Science
- Class Amino sugars; Antihyperlipidaemics; Drug conjugates; Small interfering RNA
- Mechanism of Action PCSK9 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Hyperlipidaemia
Most Recent Events
- 31 May 2023 RBD 7022 is available for licensing as of 30 May 2023. https://www.ribolia.com/En/bd-and-collaboration
- 31 May 2023 Suzhou Ribo Life Science has patent protection for small RNAi technologies in China (Suzhou Ribo Life Science pipeline, June 2023)
- 17 May 2023 Phase-I clinical trials in Hyperlipidaemia in China (SC) (NCT05912296)